OncoMatch/Clinical Trials/NCT06699771
Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies
Is NCT06699771 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including GCC2005 and Cyclophosphamide for lymphoma, t-cell.
Treatment: GCC2005 · Cyclophosphamide · Fludarabine — This is a Phase 1 (a and b), first in human (FIH), single-arm, open-label, multicenter study to evaluate the safety, tolerability and efficacy of GCC2005 in the treatment of patients with relapsed/refractory (R/R) NK or T-cell malignancies who have received at least two prior lines of therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD5 overexpression
relapsed or refractory CD5+ NK and T-cell originated malignancies
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: cytotoxic chemotherapy
relapsed or refractory disease previously treated with two or more lines of standard chemotherapies and there is no longer any treatment option considered as assessed by the Investigator
Cannot have received: CAR-T cell therapy
Patients who have had prior CAR-T or CAR-NK therapies
Cannot have received: CAR-NK cell therapy
Patients who have had prior CAR-T or CAR-NK therapies
Cannot have received: hematopoietic growth factor therapy
Exception: within 14 days prior to Screening
Patients who have used hematopoietic growth factor therapy within 14 days prior to Screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify